The call outlined significant strategic shifts and growth potential through the SCN acquisition and pediatric product line, but financial challenges remain with declining service revenue, increased losses, and reduced cash reserves. The Rebis alliance's underperformance also highlights potential integration risks.

Company Guidance -

Q2 2025

During the first quarter of 2025 earnings call, Vivos Therapeutics provided guidance on several key metrics and strategic developments. CEO Kirk Huntsman highlighted a significant pivot in their business model, focusing on creating alliances with or acquiring sleep medical providers to drive sales of their OSA treatment appliances and diversify revenue. Product sales, particularly in the pediatric guide appliance line, saw an 87% increase in arches shipped compared to the previous year, despite an 8% rise in product revenue due to lower price points. The company anticipates closing the acquisition of the Sleep Center of Nevada, which tests approximately 3,000 patients monthly for sleep disorders, within the next month or two. This acquisition is expected to be accretive to revenue and gross profit, with an anticipated net contribution margin of 50% or better. Vivos has signed a non-binding term sheet for a $7.5 million senior loan to support this acquisition and is actively seeking a $1.5 million equity infusion. The company also reported a $3.9 million net loss for the first quarter of 2025, with total revenue decreasing to $3 million from $3.4 million in the prior year, reflecting their strategic pivot and cost-cutting initiatives.

Pediatric Guide Appliance Line Growth

Total arches shipped grew 87% from 1,996 in the same period last year to 3,736 this year. Product revenue for the quarter was up 8% due to lower price points on certain pediatric products.

SCN Acquisition Potential

Acquisition of the Sleep Center of Nevada is expected to close in the next month or two, potentially adding diagnostics and treatment revenue. SCN sees approximately 3,000 sleep patients a month.

Strategic Shift to Sleep Medical Providers

Transitioning to a model of creating strategic alliances or acquiring sleep medical providers to drive sales and diversify revenue.

Cost Reduction Initiatives

Sales and marketing expenses decreased from $700,000 to $400,000, and total operating expenses decreased by 5% compared to last year due to cost-cutting initiatives.

Vivos Therapeutics (VVOS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VVOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.38 / -	-0.6	―	―	―
May 15, 2025	2025 (Q1)	- / -0.45	-1.63	72.39% (+1.18)	―
Mar 31, 2025	2024 (Q4)	-0.40 / -0.45	-1.63	72.39% (+1.18)	―
Nov 14, 2024	2024 (Q3)	-0.66 / -0.40	-1.75	77.14% (+1.35)	―
Aug 14, 2024	2024 (Q2)	-1.05 / -0.60	-4.5	86.67% (+3.90)	―
May 14, 2024	2024 (Q1)	-1.18 / -1.63	-1.75	6.86% (+0.12)	―
Mar 28, 2024	2023 (Q4)	-1.91 / -3.14	-4.75	33.89% (+1.61)	―
Nov 14, 2023	2023 (Q3)	-3.00 / -1.75	-6.5	73.08% (+4.75)	―
Aug 16, 2023	2023 (Q2)	-3.63 / -4.50	-8.25	45.45% (+3.75)	―
Jun 08, 2023	2023 (Q1)	-4.50 / -1.75	-6.5	73.08% (+4.75)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VVOS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$3.06	$2.54	-16.99%
Mar 31, 2025	$2.85	$2.63	-7.72%
Nov 14, 2024	$3.12	$2.84	-8.97%
Aug 14, 2024	$2.37	$2.25	-5.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vivos Therapeutics (VVOS) report earnings?

Vivos Therapeutics (VVOS) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is Vivos Therapeutics (VVOS) earnings time?

Vivos Therapeutics (VVOS) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VVOS EPS forecast?

VVOS EPS forecast for the fiscal quarter 2025 (Q2) is -0.38.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing